Population genomics in peripartum cardiomyopathy
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11623271 · Data updated 2026-11-12
A gene-focused study to understand why some women develop heart failure around and after pregnancy, with an emphasis on African ancestry.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 17, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $795,306 |
| NIH project number | 7R01HL174912-02 |
| Project ID | NIH-11623271 on NIH RePORTER |
Who could benefit from this research
✓Could help
Women around late pregnancy or early postpartum, especially those with African ancestry or African descent.
✕Less likely to help
Women without PPCM or genetic risk factors may not benefit directly.
What this research studies
This project looks at how rare monogenic variants and common genetic factors together influence risk of peripartum cardiomyopathy (PPCM) in diverse populations. Researchers will analyze genetic data to see how TTN mutations and polygenic risk scores relate to PPCM onset and progression. The goal is to improve early detection and risk prediction so women at risk can be monitored and managed more effectively during pregnancy and the postpartum period.
Why it matters
Potential benefit: If successful, it could lead to earlier identification of women at high risk for PPCM and more personalized monitoring or interventions.
How similar studies have gone: Previous work showed monogenic and polygenic factors contribute to PPCM, making this a promising but still developing approach.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Aragam, Krishna G — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Aragam, Krishna G
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.